Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
About Artivion, Inc. (NYSE: AORT)
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a prominent medical device company dedicated to developing elegant and straightforward solutions addressing the complex challenges faced by cardiac and vascular surgeons in treating aortic diseases. The company offers a wide array of aortic-centric products, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, distributed in over 100 countries worldwide.
Recent Achievements and Financial Performance:
- For the third quarter of 2023, Artivion reported revenues of $87.9 million, marking a 14% increase year-over-year, with notable growth in aortic stent grafts and On-X mechanical heart valves.
- Completed enrollment in the PERSEVERE clinical trial, targeting PMA approval for the AMDS Hybrid Prosthesis by 2025, showcasing significant reductions in all-cause mortality and major adverse events.
- Announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and further optimize the capital structure, highlighting the company's strategic growth initiatives.
Product Innovation and Clinical Trials:
- The On-X Aortic Heart Valve Low INR post-market study demonstrated superior patient outcomes, significantly reducing major bleeding events compared to historic controls.
- Artivion's product portfolio includes innovative solutions like the AMDS Hybrid Prosthesis, aimed at improving outcomes for patients with acute DeBakey Type I aortic dissections.
With a strong focus on clinical efficacy and market expansion, Artivion continues to be a pivotal player in the cardiac and vascular surgery market, striving to deliver life-saving products and technologies that improve patient outcomes.
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) announced new clinical data for On-X Aortic Heart Valve and AMDS at the 104th AATS Annual Meeting. 5-year real-world safety and efficacy data from On-X Aortic Valve show better patient outcomes than predicted. AMDS PERSEVERE Trial data demonstrate positive aortic remodeling outcomes. On-X Aortic Valve remains safe with low-dose warfarin. AMDS prevents DANE tears and induces positive aortic remodeling.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) will release its first quarter 2024 financial results on May 6, 2024, followed by a teleconference call and webcast hosted by Pat Mackin, the Chairman, President, and CEO. Investors can access the live event by dialing 201-689-8261 or visiting the company's website. The earnings press release with financial and statistical information will be available on the Artivion website for further details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary
Artivion, Inc. (AORT) will participate in the 23rd Annual Needham Virtual Healthcare Conference with a virtual fireside chat on April 8, 2024. The event will focus on the company's expertise in cardiac and vascular surgery for aortic disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
News
Rhea-AI Summary
Artivion, Inc. (AORT) to participate in Oppenheimer Healthcare Conference. Virtual fireside chat on aortic disease scheduled for March 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
Artivion, Inc. (AORT) reports a strong financial performance in Q4 2023, with revenue reaching $93.7 million, a 15% increase YoY. The company achieved revenue of $354.0 million for the full year 2023, showing a 12% growth on a non-GAAP constant currency basis. Despite a net loss in Q4, non-GAAP net income was $4.6 million. Artivion also closed a $350.0 million credit agreement and presented positive results from the AMDS PERSEVERE clinical trial. The company projects revenue growth of 8-12% in 2024, aiming for non-GAAP adjusted EBITDA to be in the range of $68 to $72 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT), a cardiac and vascular surgery company, will release its Q4 and full year 2023 financial results on February 15, 2024. A teleconference call and webcast will be held to discuss the results, hosted by Pat Mackin, the Chairman, President, and CEO. The press release will contain financial and statistical information for the completed quarter and full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) presents results from the AMDS PERSEVERE clinical trial, demonstrating a 72% reduction in all-cause mortality and a 52% reduction in primary major MAEs at 30 days compared to the current standard of care. The trial also showed statistically significant reduction in all-cause mortality and primary major adverse events, as well as excellent results for secondary endpoints. The AMDS device significantly reduces 30-day MAEs in ADTI patients complicated by malperfusion and helps prevent DANE, with no occurrence of distal anastomotic new entry. The company is excited to deliver this revolutionary technology to patients with no comparable alternatives as soon as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) has closed a $350 million non-dilutive credit agreement with Ares Management Credit funds, consisting of senior secured, interest-only credit facilities with 6-year maturities. The agreement includes an initial $190 million term loan, a $60 million revolving credit facility, and an additional $100 million in unfunded delayed draw term loan commitments. The company plans to use the funds to address debt maturities and optimize its capital structure. The agreement reflects the company's confidence in its business outlook and aims to deliver significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) appoints Lance A. Berry as Chief Financial Officer, reaffirms financial guidance for 2023. Mr. Berry brings extensive experience from Wright Medical Group N.V. and a strong track record in driving shareholder value. He replaces retiring CFO D. Ashley Lee, who played a pivotal role in the Company's significant growth since 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) completes enrollment in the PERSEVERE clinical trial for the AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissection, aiming for FDA premarket approval. Dr. Wilson Szeto praises the potential of AMDS as a practice-changing advancement, while Pat Mackin expresses optimism for achieving PMA approval in the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
FAQ
What is the current stock price of Artivion (AORT)?
The current stock price of Artivion (AORT) is $28.48 as of December 20, 2024.
What is the market cap of Artivion (AORT)?
The market cap of Artivion (AORT) is approximately 1.2B.
What products does Artivion, Inc. offer?
Artivion's product portfolio includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues.
Where is Artivion, Inc. headquartered?
Artivion is headquartered in suburban Atlanta, Georgia.
What are some recent clinical achievements of Artivion?
Recent achievements include superior results from the On-X Aortic Heart Valve Low INR post-market study and the completion of enrollment in the PERSEVERE clinical trial for the AMDS Hybrid Prosthesis.
What was Artivion's revenue growth in the third quarter of 2023?
Artivion achieved a revenue of $87.9 million in the third quarter of 2023, marking a 14% increase year-over-year.
How is Artivion addressing its debt maturities?
Artivion announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and optimize its capital structure.
In how many countries does Artivion market its products?
Artivion markets and sells its products in over 100 countries worldwide.
What is the focus of Artivion's clinical trials?
Artivion's clinical trials focus on developing products like the AMDS Hybrid Prosthesis to improve outcomes in treating aortic dissections and other aortic diseases.
What are the key products in Artivion's portfolio?
Key products include the On-X mechanical heart valves, aortic stent grafts, surgical sealants, and implantable cardiac and vascular human tissues.
What are the benefits of the On-X Aortic Heart Valve?
The On-X Aortic Heart Valve has demonstrated a significant reduction in major bleeding events, offering improved patient outcomes.
When does Artivion expect to achieve PMA approval for the AMDS Hybrid Prosthesis?
Artivion anticipates PMA approval for the AMDS Hybrid Prosthesis by 2025, following the successful completion of the PERSEVERE clinical trial.
Artivion, Inc.
NYSE:AORT
AORT Rankings
AORT Stock Data
1.17B
36.71M
5.51%
87.55%
7.67%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States of America
KENNESAW